Role of EGFR, HER2 and PIK3CA alterations in male breast cancer

被引：0
|
作者：
Rizzolo, P. [1 ]
Silvestri, V. [1 ]
Falchetti, M. [1 ]
Zanna, I. [2 ]
Palli, D. [2 ]
Ottini, L. [1 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] Canc Prevent & Res Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 05期
关键词：
D O I：
10.1016/S1359-6349(10)70901-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines
    Laterza, M. M.
    Belli, V.
    Ciaramella, V.
    Martinelli, E.
    Morgillo, F.
    Ventriglia, J.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Diana, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Decreased PTEN expression and PIK3CA mutations in HER-2 positive breast cancer.
    Koninki, K.
    Kauraniemi, P.
    Pitkanen, J.
    Isola, J.
    Tanner, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S211 - S211
  • [24] Investigation of alterations in PIK3CA and OCT-4 gene expression in breast cancer
    Dirican, Ebubekir
    Kankaya, Burak
    Buyukasik, Suleyman
    Alis, Halil
    Velidedeoglu, Mehmet
    Ilvan, Sennur
    Ilvan, Ahmet
    GENE REPORTS, 2020, 21
  • [25] BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
    Nam, Soo Kyung
    Yun, Sumi
    Koh, Jiwon
    Kwak, Yoonjin
    Seo, An Na
    Park, Kyoung Un
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Woo Ho
    Lee, Hye Seung
    PLOS ONE, 2016, 11 (03):
  • [26] KRAS, EGFR AND PIK3CA mutation in triple negative breast carcinomas
    Erdogan, G.
    Ozcan, M.
    Karaveli, F. S.
    Pestereli, H. E.
    INTERNATIONAL JOURNAL OF MEDICAL RESEARCH & HEALTH SCIENCES, 2016, 5 (03): : 95 - 104
  • [27] Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate
    Brand, Toni M.
    Wheeler, Deric L.
    CANCER BIOLOGY & THERAPY, 2011, 11 (03) : 368 - 370
  • [28] Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
    Katherine E. Hutchinson
    Jessica W. Chen
    Heidi M. Savage
    Thomas J. Stout
    Frauke Schimmoller
    Javier Cortés
    Susan Dent
    Nadia Harbeck
    William Jacot
    Ian Krop
    Sally E. Trabucco
    Smruthy Sivakumar
    Ethan S. Sokol
    Timothy R. Wilson
    Genome Medicine, 15
  • [29] Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Kai, Yuichiro
    Ohi, Yasuyo
    Toyoshima, Satoshi
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ONCOLOGY, 2017, 93 (01) : 51 - 61
  • [30] PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
    Ilenia Migliaccio
    Marta Paoli
    Emanuela Risi
    Chiara Biagioni
    Laura Biganzoli
    Matteo Benelli
    Luca Malorni
    npj Breast Cancer, 8
12345